Genmab AS (GMAB):企業の財務・戦略的SWOT分析

◆英語タイトル:Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1654
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Genmab AS (GMAB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Its products are based on three next generation antibody technologies, namely, HexaBody, DuoBody and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

Mar 26,2020 Passing of Genmab Annual General Meeting
Mar 10,2020 Genmab announces appointment of Anthony Mancini to newly created position of chief operating officer
Feb 21,2020 Genmab Board of Directors Chairman to Step Down
Feb 19,2020 Genmab publishes 2019 annual report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Genmab AS – Key Facts
Genmab AS – Key Employees
Genmab AS – Key Employee Biographies
Genmab AS – Major Products and Services
Genmab AS – History
Genmab AS – Company Statement
Genmab AS – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Genmab AS – Business Description
R&D Overview
Genmab AS – Corporate Strategy
Genmab AS – SWOT Analysis
SWOT Analysis – Overview
Genmab AS – Strengths
Genmab AS – Weaknesses
Genmab AS – Opportunities
Genmab AS – Threats
Genmab AS – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genmab AS, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 26, 2020: Passing of Genmab Annual General Meeting
Mar 10, 2020: Genmab announces appointment of Anthony Mancini to newly created position of chief operating officer
Feb 21, 2020: Genmab Board of Directors Chairman to Step Down
Feb 19, 2020: Genmab publishes 2019 annual report
Dec 05, 2019: Grant of restricted stock units to board members, management and employees and grant of warrants to employees in Genmab
Nov 06, 2019: Genmab announces financial results for the first nine months of 2019
Oct 30, 2019: David Eatwell to retire as chief financial officer of Genmab
Oct 14, 2019: Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
Sep 10, 2019: Genmab partners Tempus to identify new cancer targets
Sep 09, 2019: Genmab and Tempus enter into strategic collaboration agreement
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Genmab AS, Key Facts
Genmab AS, Key Employees
Genmab AS, Key Employee Biographies
Genmab AS, Major Products and Services
Genmab AS, History
Genmab AS, Subsidiaries
Genmab AS, Key Competitors
Genmab AS, Ratios based on current share price
Genmab AS, Annual Ratios
Genmab AS, Annual Ratios (Cont...1)
Genmab AS, Interim Ratios
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genmab AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Genmab AS, Performance Chart (2015 - 2019)
Genmab AS, Ratio Charts
Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genmab AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Genmab AS (GMAB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ceska pojistovna a.s.:企業の戦略的SWOT分析
    Ceska pojistovna a.s. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Messer Cutting Systems GmbH:企業の戦略的SWOT分析
    Messer Cutting Systems GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • J & J Snack Foods Corp:企業の戦略・SWOT・財務情報
    J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report Summary J & J Snack Foods Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Turbo Power Systems Ltd:企業の戦略的SWOT分析
    Turbo Power Systems Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Zehnder Group AG (ZEHN):企業の財務・戦略的SWOT分析
    Zehnder Group AG (ZEHN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • SNC-Lavalin Group Inc.:企業の戦略・SWOT・財務情報
    SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report Summary SNC-Lavalin Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bank of Montreal:企業のM&A・事業提携・投資動向
    Bank of Montreal - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of Montreal Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • MediGene AG (MDG1):製薬・医療:M&Aディール及び事業提携情報
    Summary MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business deve …
  • Public Financial Holdings Ltd (626)
    Public Financial Holdings Ltd (626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Shine Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Shine Medical Technologies Inc (Shine Medical) is a manufacturer and supplier of medical tracers and cancer treatment elements. The company’s products include molybdenum-99 is the parent isotope of technetium 99m for diagnosing and staging multitude of diseases, including cancer and heart di …
  • Brioche Pasquier S.A.:企業の戦略・SWOT・財務分析
    Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report Summary Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Boardriders, Inc:企業の戦略的SWOT分析
    Boardriders, Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Lloyds Banking Group Plc:企業の戦略・SWOT・財務情報
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ascom Holding AG:企業のM&A・事業提携・投資動向
    Ascom Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ascom Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Aquila Resources Ltd:企業の戦略・SWOT・財務分析
    Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Aquila Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Amphastar Pharmaceuticals Inc (AMPH):企業の財務・戦略的SWOT分析
    Amphastar Pharmaceuticals Inc (AMPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Micell Technologies Inc:製品パイプライン分析
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optim …
  • Theravance Biopharma Inc (TBPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company. Its flagship product, Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to Staphylococcus aureus and other Gram-p …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Banca Transilvania S.A.:企業の戦略・SWOT・財務情報
    Banca Transilvania S.A. - Strategy, SWOT and Corporate Finance Report Summary Banca Transilvania S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆